Sept 23 (Reuters) -

McKesson on Tuesday raised its profit forecast, as

the U.S. drug distributor aims to focus on high-margin

businesses such as cancer medicines to boost growth.

The Texas-based firm now expects its adjusted earnings

to range between $38.05 and $38.55 per share for fiscal 2026, up

from its previous forecast of $37.10 to $37.90.

The company's strong operational track record and

disciplined execution would help it deliver "meaningful impact

across the healthcare ecosystem," CEO Brian Tyler said.

McKesson last week laid out plans to reorganize its business

into four segments starting this quarter.